Nonsteroidal anti-inflammatory drugs and the risk of keratinocyte skin cancer among women: Is there a link?

Cancer

Volumn 119, Issue 7, 2013, Pages 1446-

  Zalaudek, Iris ^a,b   Argenziano, Giuseppe ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

CANCER INCIDENCE; CANCER RISK; DRUG EFFICACY; DRUG USE; DYSMENORRHEA; FEMALE; HUMAN; KERATINOCYTE; KERATINOCYTE SKIN CANCER; LETTER; PRIORITY JOURNAL; RISK REDUCTION; SEX DIFFERENCE; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; MALE; SKIN NEOPLASMS;

EID: 84875382633     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27764     Document Type: Letter

References (5)

1. Johannesdottir SA, Chang ET, Mehnert F, et al. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer. 2012; 118: 4768-4776.
2. Salasche SJ,. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol. 2000; 42: 4-7.
3. Frost CA, Green AC, Williams GM,. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol. 1998; 139: 1033-1039.
4. Durain D,. Primary dysmenorrhea: assessment and management update. J Midwifery Womens Health. 2004; 49: 520-528.
5. Clayton AH,. Symptoms related to the menstrual cycle: diagnosis, prevalence, and treatment. J Psychiatr Pract. 2008; 14: 13-21.